Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

INTRODUCTION: Despite high cure rates with standard treatment, 30% patients with Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell transplantation (HCT) is considered standard of care. Brentuximab Vedotin (Bv) in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Vivek S., Bajaj, Rajat, Raina, Vasundhara, Kumar, Jeevan, Bhave, Saurabh J., Sukumaran Nair, Reghu K., Nag, Arijit, Arun, Indu, Zameer, Lateef, Dey, Debdeep, Arora, Neeraj, Parihar, Mayur, Das, Jayanta, Achari, Rimpa B., Mishra, Deepak K., Chandy, Mammen, Nair, Reena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814627/
https://www.ncbi.nlm.nih.gov/pubmed/35127505
http://dx.doi.org/10.3389/fonc.2021.796270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814627/
https://www.ncbi.nlm.nih.gov/pubmed/35127505
http://dx.doi.org/10.3389/fonc.2021.796270

Ejemplares similares